Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis

被引：0
|
作者：
Egeberg, A. [1 ]
Ottosen, M. B. [1 ]
Gniadecki, R. [2 ]
Broesby-Olsen, S. [3 ,4 ]
Dam, T. [5 ]
Bryld, L. E. [6 ]
Rasmussen, M. K. [7 ]
Skov, L. [1 ]
机构：
[1] Herlev & Gentofte Hosp, Dept Dermatol & Allergy, Hellerup, Denmark
[2] Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark
[3] Odense Univ Hosp, Dept Dermatol, Odense, Denmark
[4] Odense Univ Hosp, Allergy Ctr, Odense, Denmark
[5] Skin Clin, Nykobing, Denmark
[6] Roskilde Hosp, Dept Dermatol, Roskilde, Denmark
[7] Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2017年 / 177卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P075
引用
收藏
页码：E284 / E285
页数：2
相关论文
共 50 条
  • [1] Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
    Egeberg, A.
    Ottosen, M. B.
    Gniadecki, R.
    Broesby-Olsen, S.
    Dam, T. N.
    Bryld, L. E.
    Rasmussen, M. K.
    Skov, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (02) : 509 - 519
  • [2] Efficacy and safety of infliximab biosimilars in the treatment of patients with moderate-to-severe psoriasis
    Chasapi, Vasiliki
    Routsi, Eleni
    Lantzou, Sotiria
    Papoutsaki, Marina
    Panagakis, Pantelis
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [3] The role of biologics in the treatment of moderate-to-severe plaque psoriasis
    Puig, Lluis
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2017, 152 (01): : 28 - 35
  • [4] Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis
    Egeberg, Alexander
    Bryld, Lars Erik
    Skov, Lone
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (01) : 173 - 178
  • [5] Efficacy and Safety of Ixekizumab in Pediatric Patients with Moderate-to-Severe Plaque Psoriasis
    Paller, Amy
    Seyger, Marieke
    Alejandro Magarinos, Gabriel
    Bagel, Jerry
    Keller, Stuart
    Capriles, Claudia Rodriguez
    Gallo, Gaia
    Edson-Heredia, Emily
    Li, Lingnan
    Xu, Wen
    Papp, Kim
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 17 - 17
  • [6] Comment on "Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis"
    Lebwohl, Mark G.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (06) : E377 - E377
  • [7] Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis
    Leman, J.
    Burden, A. D.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 : 12 - 20
  • [8] Real world data with secukinumab for moderate-to-severe plaque psoriasis: Evaluation of safety, efficacy and drug survival in 50 patients
    Gkini, Maria-Angeliki
    Bewley, Anthony
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB114 - AB114
  • [9] Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis
    Golhen, Klervi
    Winskill, Carolyn
    Theiler, Martin
    Buettcher, Michael
    Yeh, Yu-Hsin
    Zhang, Nancy
    Welzel, Tatjana
    Pfister, Marc
    FRONTIERS IN MEDICINE, 2022, 9
  • [10] Drug survival of secukinumab for moderate-to-severe plaque psoriasis: reply from authors
    Egeberg, A.
    Skov, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (01) : 222 - 223
12345